Dementia is not a specific disease. It is a descriptive term for a collection of symptoms that can be caused by a number of disorders that affect the brain. People with dementia have significantly impaired intellectual functioning that interferes with normal activities and relationships. They also lose their ability to solve problems and maintain emotional control, and they may experience personality changes and behavioral problems, such as agitation, delusions, and hallucinations.
Ground-breaking new Curtin University-led research has discovered a likely cause of Alzheimer's disease, in a significant finding that offers potential new prevention and treatment opportunities for Australia's second-leading cause of death.
AD, the most frequent cause of dementia, affects an estimated 24 million people worldwide. With very limited treatment options, scientists are looking for ways to understand the disease better.
In a new study, researchers have identified a new pathway that cells use to eliminate cellular waste that otherwise would damage the cell’s genes.
According to recent research, investigating some inflammatory proteins will enable diagnosis of the earlier onset and progression of Alzheimer’s disease.
Research has revealed higher cholesterol supply from astrocytes to neurons in the model of Alzheimer’s disease (AD) brains.
Scientists from the Icahn School of Medicine at Mount Sinai published the first of its kind research in the field of addiction genetics employing a multi-omics method to offer a huge list of causal candidate genes linked with alcohol consumption and alcohol use disorder (AUD).
Experimental research has shown that amyloid-beta, the Alzheimer’s protein, accumulates within nerve cells.
Using data from two large, long-running study projects in the Puget Sound region -; one that began in the late 1970s measuring air pollution and another on risk factors for dementia that began in 1994 -; University of Washington researchers identified a link between air pollution and dementia.
Alzheimer’s disease (AD) is a neurological condition that leads to dementia worsening with age as patients show memory, cognitive, and psychological deficits.
Scientists have found that the brain lacks the ability to maintain the cholesterol-rich myelin sheath that insulates neurons when a protein is absent.
A new study has demonstrated the removal of damaged mitochondria from the brain cells of mice treated with a small molecule compound for Parkinson’s disease.
Researchers have introduced a novel gene therapy program that could set the stage for new treatments for neurodegenerative diseases.
Studies conducted on patients’ tissue as well as mini-brains created from stem cells have provided a better insight into Alzheimer’s disease.
The largest study to date has provided a better understanding of how genes are controlled in dementia, including the identification of 84 novel genes associated with the condition.
Scientists say naked mole rats - a rodent native to West Africa - may hold the key to new treatments for degenerative diseases such as cancer and dementia.
Liang Zhan, assistant professor of electrical and computer engineering at Pitt's Swanson School of Engineering, received a $500,000 CAREER award from the National Science Foundation to develop computational tools that improve our understanding of the human brain.
Levels of a protein called neurofilament light chain (NfL) in the blood can identify those who might have neurodegenerative diseases such as Down's syndrome dementia, motor neuron disease (ALS) and frontotemporal dementia, when clinical symptoms are not definitive.
In a world first, scientists from the University of Sussex have recorded blood oxygen levels in the hippocampus and provided experimental proof for why the area, commonly referred to as 'the brain's memory center', is vulnerable to damage and degeneration, a precursor to Alzheimer's disease.
Alzheimer’s disease is the most prevalent form of dementia distinguished by the accumulation of amyloid plaques in the brain.
The progression of Parkinson’s disease (PD) is an important factor in patients’ well-being and clinical trials.